Apimeds Pharmaceuticals US, Inc (APUS) Valuation — DCF, Graham & Comparables

Apimeds Pharmaceuticals US, Inc (APUS) — Price $1.60 HealthcareBiotechnology — AMEX

Latest reported results:

Valuation dashboard for Apimeds Pharmaceuticals US, Inc (APUS) with P/E N/A, P/B 0.02, EV/EBITDA -0.33 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.

Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure. The company was incorporated in 2020 and is based in Matawan, New Jersey. Apimeds Pharmaceuticals US, Inc. operates as a subsidiary of Inscobee., Inc.

Analysis Summary

Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.

At the current price of $1.60, APUS has negative trailing earnings (P/E not meaningful) and an ROE of -58.98%. Market capitalisation stands at $2M.

Balance sheet quality for APUS: current ratio of 1.3. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.

Valuation Ratios

Price / Book0.02
EV / EBITDA-0.33
Dividend Yield0.00%

Valuation Models

DCF Fair Value$-6.43
vs Current Price-502.0%

Peer Comparison

SymbolCompanyMarket CapP/EP/BROE
APUSApimeds Pharmaceuticals US, Inc$2M0.02-59.0%
0QZU.LVertex Pharmaceuticals Incorporated$131.8B
VRTXVertex Pharmaceuticals Incorporated$130.3B29.686.4523.3%
0R2M.LRegeneron Pharmaceuticals, Inc.$84.0B
REGNRegeneron Pharmaceuticals, Inc.$79.8B18.792.5713.8%
ARGXargenx SE$61.2B36.307.4021.7%
MRNAModerna, Inc.$57.8B1.34-39.2%
RVMDRevolution Medicines, Inc.$41.7B15.96-96.4%

Price

Price$1.60
Market Cap$2M
ExchangeAMEX
CountryUS

Profitability

Return on Equity-58.98%
Return on Invested Capital-15.89%
Return on Assets-45.58%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%

Related companies: ANTX · IGC · MIRA · MLSS · MYO · NXTC · POCI

Explore sector: Healthcare · Biotechnology

More sections of APUS: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events

Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks